Abstract
Throughout the human experience, diseases caused by pathogenic bacteria have exerted an enormous negative impact on society. Today, for example, approximately one third of the world’s population is infected with Mycobacterium tuberculosis and tuberculosis remains the leading cause of death in the world from infectious disease (Bloom, 1994). The emergence of effective antibacterial agents, from penicillin to more contemporary drugs, was initially thought to mark an end to the burden of microbial disease. However, subsequent events have illustrated the resiliency of bacteria to environmental pressures, including the threat of antibacterial agents.
Author to whom all correspondence should be addressed
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ayliffe, G. A. J., 1997, The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus, Clin. Infect. Dis 24 (Suppl. 1): S74.
Barbachyn, M. R., Hutchinson, D. K., Brickner, S. J., Cleek, G. J., Garmon, S. A., Grega, K. C., Hendges, S. K., Lindberg, T. J., Manninen, P. R., Munesada, K., Reid, R. J., Thomas, R. C, Toops, D. S., and Ulanowicz, D. A., 1996, Synthesis and SAR of novel antibacterial oxazolidinones, Abstracts of Papers, 14th International Symposium on Medicinal Chemistry, Maastricht, The Netherlands, Abstract No. SL-09.2.
Barbachyn, M. R., Hutchinson, D. K., Brickner, S. J., Cynamon, M. H., Kilburn, J. O., Klemens, S. P., Glickman, S. E., Grega, K. C, Hendges, S. K., Toops, D. S., Ford, C. W., and Zurenko, G. E., 1996, Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity, J. Med. Chem 39: 680.
Barbachyn, M. R., Toops, D. S., Grea, K. C., Hendges, S. K., Ford, C. W., Zurenko, G. E., Hamel, J. C, Schaadt, R. D., Stapert, D., Yagi, B. H., Buysse, J. M., Demyan, W. F., Kilburn, J. O., and Glickman, S. E., 1996, Synthesis and antibacterial activity of new tropone-substituted phenyloxazolidinone antibacterial agents. 2. Modification of the phenyl ring — the potentiating efect of fluorine substitution on in vivo activity., Bioorg. Med. Chem. Lett 6: 1009.
Bloch, A. B., Simone, P. M., McCray, E., and Castro, K. G., 1996, Preventing multidrug-resistant tuberculosis, JAMA 275: 487.
Bloom, B. R., 1994, Tuberculosis: Pathogenesis, Protection, and Control, ASM Press: Washington, D.C.
Breiman, R. F., Butler, J. C., Tenover, F. C., Elliott, J. A., and Facklam, R. R., 1994, Emergence of drug-resistant pneumococcal infections in the United States, JAMA 271: 1831.
Brickner, S. J., 1996, Oxazolidinone antibacterial agents, Cur. Pharm. Design 2:175.
Brickner, S. J., Hutchinson, D. K., Barbachyn, M. R., Manninen, P. R., Ulanowicz, D. A., Garmon, S. A., Grega, K. C., Hendges, S. K., Toops, D. S., Ford, C. W., and Zurenko, G. E., 1996, Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections, J. Med. Chem 39: 673.
Brickner, S. J., Manninen, P. R., Ulanowicz, D. A., Lovasz, K. D., and Rohrer, D. C., 1993, Multicyclic fused-ring oxazolidinone antibacterial agents, Abstracts of Papers, 206th National Meeting of the American Chemical Society, Chicago, IL, American Chemical Society: Washington, D.C, ORGN 089.
Brumfitt, W. and Hamilton-Miller, J. M. T., 1992, Antibacterial oxazolidinones: in vitro activity of a new analogue, E3709, Diagn. Microbiol. Infect. Dis 15: 621.
Carlson, R. K., Park, C.-H., and Gregory, W. A., 1990, Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents, U.S. Patent 4,948,801.
Chopra, I., Hodgson, J., Metcalf, B., and Poste, G., 1996, New Approaches to the control of infections caused by antibiotic-resistant bacteria, JAMA 275: 401.
Chu, D. T. W. and Fernandes, P. B., 1989, Structure-activity relationships of the fluoroquinolones, Antimicrob. Agents Chemother 33: 131.
Chu, D. T. W., Plattner, J. J., and Katz, L., 1996, New directions in antibacterial research, J. Med. Chem 39: 3853.
Coque, T. M., Tomayko, J. F., Ricke, S. C., Okhyusen, P. C., and Murray, B. E., 1996, Vancomycin-resistant en-terococci from nosocomial, community, and animal sources in the United States, Antimicrob. Agents Chemother 40: 2605.
Eustice, D. C., Feldman, P. A., and Slee, A. M., 1988, The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis, Biochem. Biophys. Res. Commun 150: 965.
Eustice, D. C, Feldman, P. A., Zajac, I., and Slee, A. M., 1988, Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis, Antimicrob. Agents Chemother 32: 1218.
Eustice, D. C., Slee, A. M., 1987, Abstracts of Papers, 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY, ASM Press: Washington, D.C, Abstract No. 246.
Ford, C. W., Hamel, J. C., Wilson, D. M., Moerman, J. K., Stapert, D., Yancey, R. J., Jr., Hutchinson, D. K., Barbachyn, M. R., and Brickner, S. J., 1996, In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections, Antimicrob. Agents Chemother 40: 1508.
Frigola, J., Parés, J., Corbera, J., Vañó, M., Torrens, A., Más, J., and Valenti, E., 1993, 7-Azetidinylquinolones as antibacterial agents. Synthesis and structure-activity relationships., J. Med. Chem 36: 801, and references cited therein.
Griffith, W. P. and Ley, S. V., 1990, TPAP: tetra-n-propylammonium perruthenate, a mild and convenient oxidant for alcohols, Aldrichimica Acta 23: 13.
Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T., and Tenover, F. C., 1997, Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility, J. Antimicrob. Chemother 40: 135.
Kaldor, S. W. and Hammond, M., 1991, A mild, osmium tetraoxide-catalyzed method for the oxidation of sulfides to sulfones, Tetrahedron Lett 32: 5043.
Klemens, S. P., Sharpe, C. A., and Cynamon, M. H., 1995, Activities of two novel oxazolidinones against M. tuberculosis (MTB) in a murine model, Abstracts of Papers, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, ASM Press: Washington, D.C, Abstract No. F228.
Leonard, N. J. and Johnson, C. R., 1962, Periodate oxidation of sulfides to sulfoxides. Scope of the reaction., J. Org. Chem 27: 282.
Leclercq, R., 1997, Enterococci acquire new kinds of resistance, Clin. Infect. Dis 24 (Suppl. 1): S80.
Leclercq, R. and Courvalin, P., 1997, Resistance to glycopeptides in enterococci, Clin. Infect. Dis 24: 545.
Lin, A. H., Murray, R. W., Vidmar, T. J., and Marotti, K. R., 1997, The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin, Antimicrob. Agents Chemother 41:2127.
Martin, R., Wilcox, K. R., Campbell, C., and Ellis, H., 1997, Update: Staphylococcus aureus with reduced susceptibility to vancomycin — United States, 1997, Morbidity and Mortality Weekly Report 46: 813.
McCracken, G. H., 1996, Recent perspectives on drug-resistant Streptococcus pneumoniae, Pediatr. Infect. Dis. J 15:930.
McDonald, L. C, Kuehnert, M. J., Tenover, F. C, and Jarvis, W. R., 1997, Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications, Emerging Infectious Diseases 3: 311.
Moreno, F., Crisp, C., Jorgensen, J. H., and Patterson, J. E., 1995, Methicillin-resistant Staphylococcus aureus as a community organism, Clin. Infect. Dis 21: 1308.
Nix, D. E. and Schentag, J. J., 1988, The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics, J. Clin. Pharmacol 28: 169.
Noble, W. C., Virani, Z., and Cree, R. G. A., 1992, Co-transfer of vancomycin and other resistance genes from En-terococcus faecalis NCTC 12201 to Staphylococcus aureus, FEMS Microbiol. Lett 93: 195.
Park, C.-H., Brittelli, D. R., Wang, C. L.-J., Marsh, F. D., Gregory, W. A., Wuonola, M. A., McRipley, R. J., Eberly, V. S., Slee, A. M., and Forbes, M., 1992, Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxazolidinones. 4. Multiply-substituted aryl derivatives., J. Med. Chem 35: 1156, and references cited therein.
Reuman, M., Daum, S. J., Singh, B., Coughlin, S. A., Sedlock, D. M., Rake, J. B., and Lesher, G. Y., 1989, Synthesis and antibacterial activity of some novel l-substituted-7-pyridinyl-1,4-dihydro-4-oxoquinoline-3-car-boxylic acids, Abstracts of Papers, 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, TX, ASM Press: Washington, D.C., Abstract No. 1193.
Pawsey, S. D.; Daley-Yates, P. T.; Wajszczuk, C. P.; Stalker, D. J., 1996, Abstracts of Papers, First European Congress of Chemotherapy, Glasgow, Scotland, Abstract No. F151.
Pharmaprojects, April 12, 1995; PJB Publications, Ltd.: Richmond, Surrey, UK.
Pharmcast-International 1995, February, 7-1-484, 487.
Piper, R. C, Platte, T. F., and Palmer, J. R., unpublished results, Pharmacia & Upjohn.
DuPont’s new oxazolidinones, 1987, Scrip, 1250: 25.
Shinabarger, D. L., Marotti, K. R., Murray, R. W., Lin, A. H., Melchior, E. P., Swaney, S. M., Dunyak, D. S., De-myan, W. F., and Buysse, J. M., 1997, Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions, Antimicrob. Agents Chemother 41: 2132.
Silver, L. L. and Bostian, K. A., 1993, Discovery and development of new antibiotics: the problem of antibiotic resistance, Antimicrob. Agents Chemother 37: 377.
Slee, A. M., Wuonola, M. A., McRipley, R. J., Zajac, I., Zawada, M. J., Bartholomew, P. T., Gregory, W. A., and Forbes, M., 1987, Abstracts of Papers, 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY, ASM Press: Washington, D.C., Abstract No. 244.
Spangler, S. K., Jacobs, M. R., and Appelbaum, P. C., 1996, Activities of RPR 106972 (a new oral streptogramin), ceditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and-resistant pneumococci, Antimicrob. Agents Chemother 40: 481.
Stalker, D. J., Wajszczuk, C. P., and Batts, D. H., 1997, Linezolid safety, tolerance, and pharmacokinetics following oral dosing twice daily for 14.5 days Abstracts of Papers, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, ASM Press: Washington, D.C., Abstract No. A115.
Stalker, D. J., Wajszczuk, C. P., and Batts, D. H., 1997, Linezolid safety, tolerance, and pharmacokinetics after intravenous dosing twice daily for 7.5 days Abstracts of Papers, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, ASM Press: Washington, D.C., Abstract A116.
Tomasz, A., 1997, Antibiotic resistance in Streptococcus pneumoniae, Clin. Infect. Dis 24 (Suppl. 1): S85.
Tomasz, A., 1994, Multiple-antibiotic-resistant pathogenic bacteria, N. Engl. J. Med 330: 1247.
Voss, A., Milatovic, D., Wallrauch-Schwarz, C., Rosdahl, V. T., and Braveny, I., 1994, Methicillin-resistant Staphylococcus aureus in Europe, Eur. J. Clin. Microbiol. Infect. Dis 13: 50.
Zamkoff, J. P., Cline, K., Klemens, S. P., and Cynamon, M. H., 1995, Activity of U-100480, an oxazolidinone, against M. avium complex (MAC) infection in beige mice, Abstracts of Papers, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, ASM Press: Washington, D.C., Abstract No. F229.
Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E., Hutchinson, D. K., Barbachyn, M. R., and Brickner, S. J., 1996, In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents, Antimicrob. Agents Chemother 40: 839.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Barbachyn, M.R. et al. (1998). Design, Synthesis, and Evaluation of Novel Oxazolidinone Antibacterial Agents Active Against Multidrug-Resistant Bacteria. In: Rosen, B.P., Mobashery, S. (eds) Resolving the Antibiotic Paradox. Advances in Experimental Medicine and Biology, vol 456. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4897-3_12
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4897-3_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7220-2
Online ISBN: 978-1-4615-4897-3
eBook Packages: Springer Book Archive